Meet ZETRON at PHARMACONEX 2026: Exploring Pharmaceutical Quality Control & Sterility Assurance Solutions

Introduction

Taking place at Cairo, Egypt's Egypt International Exhibition Center from September 1-3, 2026, PHARMACONEX 2026 is the premier pharmaceutical manufacturing exhibition in North Africa. A critical gateway for enterprises seeking to align their facilities with stringent WHO, FDA, and European GxP requirements, it anticipates over 5,000 guests and 150+ exhibitors from across the world, facilitating easy international product export. This development is indicative of a larger trend in the MENA and African regions away from reliance on imports and toward improved domestic production capacities and supply chain resilience.

A major focus at this year's event is how to reduce the high biological risks associated with sterile parenteral formulations:

• The Stakes: Some drugs can bypass the body's natural physiological barriers, such as the skin and digestive tract. Systemic toxicity, severe infection, or even death of the patient can result from any microbial, pyrogenic, or particulate contamination.
• The Limits: Industry earlier heavily relied on traditional USP <71> end-product sterility testing. However, this method has statistical limitations. It uses very small sample sizes, usually just 20 units, and requires a long 7- to 14-day incubation period, making it poor at detecting low-frequency contamination.
• Solution: Owing to these high stakes and limitations of testing methods, modern regulators are forcing a shift toward "sterility by design." This means quality cannot just be tested at the end. It must be built directly into the processing environment and validated throughout the entire manufacturing lifecycle.

Achieving complete sterility assurance takes a multi-dimensional approach. It requires careful cleanroom design, both viable and non-viable environmental monitoring, advanced barrier technologies, and validated equipment sterilization. Furthermore, because human operators are the single largest source of cleanroom contamination, automating routine quality control assays is now a critical standard to remove human intervention entirely.

Beijing Zetron Technology Co., Ltd. addresses these exact challenges. Backed by over 20 years of research and development expertise and holding over 100 patents, Zetron provides highly compliant cleanroom airborne particle sensors, filter Integrity  testers, and glove Integrity tester that are currently used in over 24 countries. All equipment is strictly assessed against WHO Good Practices for Pharmaceutical Quality Control Laboratories and PIC/S GxP requirements. Attendees are welcome to visit our booth at Hall 4, Stand G75 to get a hands-on experience and live feedback from the experts.

Modern Sterility Assurance and the Regulatory Landscape

Transitioning to a Holistic Contamination Control Strategy (CCS)

The 2022 revision of EU GMP Annex 1 was a significant regulatory shift. It calls for sterile drug manufacturers to have a holistic, facility-wide Contamination Control Strategy (CCS). A CCS ensures that safety measures are not viewed as isolated measures but rather as a holistic risk management of microbial, particulate, and pyrogenic contamination throughout the entire lifecycle of a product. A facility’s CCS is a living, dynamic document. It should be continuously updated with environmental monitoring trends, microbiological data, and corrective/preventive action (CAPA) systems to capture process drift or early warning signals of contamination.

Under these new rules, manufacturers must scientifically justify, document, and validate their technical choices, such as:

• High-Efficiency Particulate Air (HEPA) filter selection
• Air pressure differentials
• The deployment of Isolators or Restricted Access Barrier Systems (RABS)

While aseptic processing is still necessary for heat-sensitive biopharmaceuticals, terminal sterilization such as autoclaving at 121°C for 15–20 minutes remains the preferred method by regulators because it provides a higher Sterility Assurance Level (SAL) of 10⁻⁶.

However, the ISO/TS 19930:2017 standard offers unique regulatory flexibility:

• It allows manufacturers of sensitive biopharmaceuticals and combination products to use alternative, greater SALs such as 10⁻⁴ or 10⁻⁵.
• This makes it possible to use "gentler" terminal sterilization cycles like sub-lethal heat or radiation as a helpful addition after aseptic filling.
• This significantly lowers patient risk without destroying sensitive active ingredients.
• To successfully implement these advanced bioburden-based sterilization validation methods, pre-sterilization bioburden must be maintained at extremely low levels, well-characterized, and continuously monitored.

A holistic CCS can be successfully implemented and governed by EU GMP Annex 1, USP <1211>, and ICH Q8, Q9, and Q10 guidelines, acting as a GxP culture enabler. It promotes cross-functional teamwork and collaborative quality risk management between engineering, QC labs, and commercial manufacturing floors.

Ensuring Data Integrity and Regulatory Traceability (FDA 21 CFR Part 11)

Data integrity is an absolute necessity in pharmaceutical quality control. Enforcement actually traces back to the 1993 FDA Guide to Inspection of Pharmaceutical Quality Control Laboratories, which established that raw laboratory records, analytical worksheets, and instrument logs are vital to ensure product quality and prevent falsified records.

Today, compliance with FDA 21 CFR Part 11 requires that all analytical instruments feature:

• Restricted electronic access via unique user IDs
• Automatic time-stamped audit trails
• Secure electronic signatures
• Tamperproof database architectures

Regulatory inspectors strictly forbid the dangerous practice of "testing into compliance."

• Common audit violations include using loose sheets of paper for temporary calculations, selectively deleting or overruling out-of-specification (OOS) data, and repeating tests without formal laboratory investigations.
• Furthermore, USP guidelines and court rulings make it clear that statistical outlier tests are completely inappropriate for chemical and biological testing results and cannot be used simply to reject inconclusive laboratory failures.
• During inspections, auditors routinely check that raw analytical data perfectly matches summary reports. Any overwritten logs, uninvestigated deviations, or use of correction fluid are classified as severe GMP violations.

To meet these strict standards, modern analytical instruments must use robust, local software controls usually powered by embedded Windows CE or Linux operating systems. They must include at least a four-tier user permission hierarchy, which is Administrator, Engineer, Operator, and Guest, to stop unauthorized test deletion or recipe editing. Under GxP guidelines, these instruments must also support secure, non-editable data exports and retain secure audit trail logs for at least 5 years.

Engineered for absolute compliance, Zetron's entire Pharmaceutical analytical equipment portfolio, including the FIT-600 Filter Integrity Tester, FIT-550 Filter Integrity Tester, and WGIT-26 Glove Integrity Tester, features native 21 CFR Part 11 and GMP compliance, complete with multi-level authority management, secure real-time printing, and unalterable audit trail logging.

Strategic Technological Solutions for Critical Quality Control

Advanced Automated Filter Integrity Testing

In aseptic processing lines where products cannot undergo terminal sterilization, the sterilizing-grade membrane filter (typically 0.22 μm) is the ultimate, final barrier preventing microbial contamination from entering the product vial. Manual filter testing is highly prone to operator variability, environmental fluctuations, and gas-flow reading errors. Because of this, microprocessor-controlled instruments like the Zetron FIT-600 Filter Integrity Tester are essential. They completely automate sensor stabilization and gas-flow rate controls, providing precise and operator-independent results.

These automated testers qualify membranes using four core, non-destructive physical test methods:

• Bubble Point: Measuring capillary pressure in wetted pores.
• Pressure Decay/Hold: Monitoring pressure drop over time.
• Diffusion Flow: Quantifying gas permeation under pressure gradients.
• Water Intrusion: Qualifying hydrophobic vent filters.

To proactively prevent downstream, sterile-side contamination, regulatory guidelines mandate upstream-side testing of wetted filters during in-process verification.

Going beyond routine cartridge filters, Zetron pushes testing limits with pioneering systems:

• The Zetron V10 can test complex ultrafiltration membrane packages and columns.
• The Zetron BGT-120 Bag Integrity Tester introduces a mature pressure-decay method recognized by ASTM F2095-01.
• The BGT-120 uses a proprietary "small, frequent air intake mode" that guarantees uniform inflation air speed, completely preventing physical stretching, thinning, or structural deformation of single-use bioprocess bags during pressurization.

Zetron offers a diverse range of equipment tailored for specific cleanroom classifications (Grades A through D). All automated testing protocols are strictly grounded in USP <1229.4>, ASTM F2095-01, and GAMP 5 computerized validation guidelines.

Table 1: Engineering & Compliance Comparison of Zetron’s Integrity Testing Portfolio

In-Situ Glove Integrity Verification in Isolators and RABS

Isolators and Restricted Access Barrier Systems (RABS) are designed to isolate operators from sterile processing zones. However, their glove-and-sleeve assemblies are highly fragile and physically stressed, making them the single primary source of cleanroom contamination. Simple visual inspections are highly unreliable because physical tears or micro-holes smaller than 100 μm are completely invisible to the eye. Yet, they easily allow microbiological and particulate ingress, violating EU GMP Grade A sterile environments.

Older, traditional leak testing methods required taking the gloves apart, which risked damaging the barrier and causing process downtime. Modern in-situ verification systems like the Zetron WGIT-26 Glove Integrity Tester solve this by testing gloves directly on the installed port. By using an integrated, self-inflating sealing gasket, the WGIT-26 Glove Integrity Tester safely seals the glove port in seconds without breaking the isolator's sterile barriers.

The Zetron WGIT-25 Glove Integrity Tester  and WGIT-26 Glove Integrity Tester harness the physics of high-resolution pressure decay:

• Using a specialized built-in pump (meaning no external gas source is needed), the system inflates the glove to working pressures ranging from 500 to 5,000 Pa.
• It then monitors pressure drops with an ultra-fine resolution of 0.1 Pa over a rapid 3-to-8 minute cycle, successfully identifying pinholes down to 100 μm.
• To drastically accelerate media fill changeover cycles, the WGIT-25/26 features custom host computer management software. This allows a single tablet or computer terminal to manage and monitor up to 10 independent wireless testing units simultaneously over a WLAN network.
• WGIT-26 has built-in temperature and pressure compensation sensors to prevent false pass/fail outcomes caused by minor cleanroom ambient fluctuations.

The WGIT-26 Glove Integrity Tester is designed to meet the ISO 14644-7 and GAMP 5 sterile cleaning validation protocols with an IP65-rated, crevice-free stainless steel casing that can withstand regular decontamination with Vaporized Hydrogen Peroxide (VPHP) easily.

Conclusion

As margins for contamination errors become refined, pharmaceutical manufacturers must look beyond manual inspections and adopt automated testing as the only way forward. “It is absolutely essential to eliminate human error to avoid catastrophic batch recalls and meet the requirements of the updated EU GMP Annex 1. A truly robust facility-wide Contamination Control Strategy connects automated filter testers, in-situ glove verifiers, and real-time environmental monitoring into one cohesive, 21 CFR Part 11-compliant data ecosystem.

Real-time air cleanliness is actively maintained by pairing integrity testers with Zetron’s advanced environmental monitoring line:

• The R320 Airborne Particle Sensor provides continuous, low-noise monitoring (28.3 L/min) across critical Grade A zones.
• Meanwhile, the high-flow B1030 laser counter quickly verifies cleanroom classification compliance by sampling a full 1 cubic meter of air in exactly 10 minutes.

Beyond simply supplying equipment, Beijing Zetron Technology Co., Ltd. serves as a deep, OEM/ODM-capable technical partner. Backed by 20 years of expertise, ISO/CE certifications, and a flawless track record of passing strict international quality audits, ZETRON is well-positioned to elevate global sterility standards.

ZETRON cordially invites all regional manufacturers, QA/QC laboratory directors, and sterility assurance experts to visit their booth at PHARMACONEX 2026, held from September 1–3, 2026, at the Egypt International Exhibition Center in Cairo.

• Attendees can experience live, hands-on demonstrations of the FIT-600 Filter Integrity Tester, the WGIT-26 Wireless Glove Tester, and the BGT-120 Bag Integrity Tester.
• Prior to the exhibition, manufacturers can initiate customized co-creation projects or request technical quotes by contacting Zetron’s engineering team directly via sales@bjzetron.com or via WhatsApp/WeChat at +86 15699785629.

Disclaimer: All technical specifications, software interfaces, and engineering parameters are grounded strictly in validated manufacturer data sheets and official international pharmacopoeial guidelines.

FAQs

Q1: What is the purpose of PHARMCONEX 2026

Developed to link the regional supply chain with global technology providers, PHARMACONEX 2026 is North Africa's leading pharmaceutical production hub. In order to achieve stringent compliance with WHO, FDA, and GxP standards, it mainly aims to drive resilient localized manufacturing and provide producers with the latest machinery and sterility assurance solutions they need.

Q2: What makes PHARMACONEX 2026 a must-attend event for pharmaceutical manufacturers in North Africa?

A: The expo acts as an important gateway for regional companies heading toward robust domestic manufacturing. It provides producers with the modern technology they need to make their cleanroom facilities compliant with demanding WHO, FDA, and European GxP regulations, thereby enabling the seamless worldwide export of sterile parenteral formulations.

Q3: How do automated integrity testers support a holistic Contamination Control Strategy (CCS)?

A: Automated systems completely remove human intervention, which is the primary source of cleanroom contamination. Instruments like the FIT-600 prevent reading errors and operator variability during critical filter checks, while ensuring all raw analytical data is secured with time-stamped audit trails to strictly meet FDA 21 CFR Part 11 requirements.